EastGate Acquisitions Participates As An Exhibitor At The Upcoming CHFA (Canadian Health & Food Association) West Expo Conference
SALT LAKE CITY and TORONTO, April 10, 2014 /PRNewswire/ -- EastGate Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical company aimed at utilizing drug delivery innovations in the development of improved novel formulations and alternative dosage forms of existing biologically active molecules announces that it will participate as an exhibitor at the upcoming CHFA West Expo Conference held in Vancouver, British Columbia, Canada. The trade show takes place between April 12th and April 13th at the Vancouver Convention Centre. EastGate's booth number is 1241 at the West Building of the Convention Centre.
The vibrant and all-encompassing CHFA West Expo is a trade only event that is open to individuals currently working within the natural health and organic products industries. The primary target audience for this show is retailers and health professionals who sell or professionally recommend natural health products or organics directly to consumers. Leading suppliers, manufacturers, distributors and brokers of natural health and organic products will exhibit at this conference. Both nationwide and international companies will participate.
"We are excited to be exhibitors at the CHFA West Expo," says Anna Gluskin, EastGate's Chief Executive Officer. "The venue attracts a highly health-related, health-conscious audience who are always looking for new products. We believe our self-emulsifying platform technology as applied to our supplement and consumer-related product line will stand out as a very different and innovative alternative to other products available today. We invite all interested parties to visit us at Booth number 1241," Anna Gluskin continues.
About EastGate Acquisitions Corporation
EastGate Acquisitions Corporation with locations in Salt Lake City, Utah and Toronto, Canada, is a biotechnology company aimed at utilizing drug delivery innovations for developing of improved novel formulations and alternative dosage forms of existing biologically active molecules. The Company's model is based on a two-tier business approach that includes development of novel pharmaceutical products and innovative dietary supplements. Both pharmaceutical products and natural supplements are developed using highly effective contemporary technologies and demonstrated already proven usefulness in improvement of bioavailability and biological action of incorporated molecules. The Company's product candidates address various pharmaceutical markets, including neurological disorders, such as epilepsy and panic attacks, infectious diseases and diabetes. Our natural dietary supplements, also an integral part of our R&D program, include compositions for glucose regulations, urinary tract health improvement, enhanced vitamin delivery and skin conditions. EastGate is working to expand its current product portfolio through targeted investments in pharmaceutical research and development. We are working closely with clinicians and patient advocate groups worldwide to identify existing health issues where EastGate's approach will be most beneficial for patient care. For more information, please visit the company's website at www.EastGatePharmaceuticals.com.
Cautionary statement on forward-looking information
All statements, other than statements of historical fact, contained or incorporated by reference in this news release constitute "forward-looking information" or "forward-looking statements" within the meaning of certain securities laws, including the provisions for "safe harbour" under the United States Private Securities Litigation Reform Act of 1995 and are based on expectations, estimates and projections as of the date of this news release.
The words "anticipates", "plans", "expects", "indicate", "intend", "scheduled", "estimates", "forecasts", "focus", "guidance", "initiative", "model", "methodology", "outlook", "potential", "projected", "pursue", "strategy", "study", "targets", or "believes", or variations of or similar such words and phrases or statements that certain actions, events or results "may", "could", "would", or "should", "might", or "way forward", "will be taken", "will occur" or "will be achieved" and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by EastGate as of the date of such statements, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies. The risks, estimates, models and assumptions contained or incorporated by reference in this news release, include those identified from time to time in the reports filed by EastGate with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. EastGate undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT:
Media Relations
1-647-692-0652
SOURCE EastGate Acquisitions Corporation
Share this article